A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

ReclutandoFase 3ClinicalTrials.gov

ID: NCT06972472Tipo: INTERVENTIONALInicio: 19 de may de 2025Fin estimado: 1 de ago de 2027

Traducción no disponible, mostrando original

Resumen

The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Have body mass index (BMI) ≥25 kilograms per square meter (kg/m2) at screening
Have type 2 diabetes
Have hemoglobin A1c (HbA1c) ≥7% and ≤10% at screening
Have a history of at least one unsuccessful dietary effort to lose body weight

Criterios de exclusión

Have an unstable body weight within 90 days prior to screening
Have type 1 diabetes
Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening
Have acute or chronic hepatitis or pancreatitis
Are taking other medications or alternative remedies to manage weight loss

Intervenciones

drug

Orforglipron

Administered orally

drug

Placebo

Administered orally

Ubicaciones

CARE - Centro de Alergia y Enfermedades Respiratorias

Buenos Aires, Argentina

Hernan Finkelstein

RECRUITING

CIPREC

Buenos Aires, Argentina

Angela Romero Zarante

RECRUITING

Centro Médico Viamonte

Buenos Aires, Argentina

Diego Aizenberg

RECRUITING

Instituto Centenario

CABA, Argentina

SUSANA SALZBERG

RECRUITING

Instituto Médico Catamarca IMEC

Rosario, Argentina

Natacha Maldonado

RECRUITING

Centro de Diagnóstico y Rehabilitación (CEDIR)

Santa Fe, Argentina

Antonio Saleme

RECRUITING

Patrocinadores

PrincipalEli Lilly and Company

Contactos

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

CONTACT

LillyTrials@Lilly.com 1-317-615-4559

Physicians interested in becoming principal investigators please contact

CONTACT

clinical_inquiry_hub@lilly.com

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Master Protocol to Investigate the Efficacy and Safety ... | EligiMed